Compare · BDX vs SRTS
BDX vs SRTS
Side-by-side comparison of Becton Dickinson and Company (BDX) and Sensus Healthcare Inc. (SRTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SRTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $58.68B, about 1577.2x SRTS ($37.2M).
- BDX has been more active in the news (11 items in the past 4 weeks vs 6 for SRTS).
- BDX has more recent analyst coverage (25 ratings vs 8 for SRTS).
- Company
- Becton Dickinson and Company
- Sensus Healthcare Inc.
- Price
- -
- -
- Market cap
- $58.68B
- $37.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 11
- 6
- Recent ratings
- 25
- 8
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Sensus Healthcare Inc.
Sensus Healthcare, Inc. manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sculptura product, a proprietary modulated robotic brachytherapy oncology therapy system that uses patented Beam Sculpting capabilities to treat various cancers during surgery; and Sentinel service program, which offers its customers protection for their systems. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons, eye shields, and disposable applicator tips, which are used to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Latest BDX
- Director Huffines Robert Luther was granted 158 units of Rights to Common Stock Under BD Deferred Compensation Plan (SEC Form 4)
- Director Byington Carrie L was granted 79 units of Rights to Common Stock Under 1996 Directors Deferral Plan (SEC Form 4)
- BD to Host Investor Day on December 10, 2026
- Chairman, CEO and President Polen Thomas E Jr exercised 20,239 shares at a strike of $178.94, returned $3,621,660 worth of shares to the company (17,246 units at $210.00) and sold $628,530 worth of shares (2,993 units at $210.00) as part of a pre-agreed trading plan (SEC Form 4)
- Becton Dickinson upgraded by Wells Fargo with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
- BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases
- BD Names Bridget Bagnato Worldwide President of Peripheral Intervention
- BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options
Latest SRTS
- CHIEF EXECUTIVE OFFICER Joseph C Sardano bought $72,108 worth of shares (30,000 units at $2.40), increasing direct ownership by 2% to 1,250,293 units (SEC Form 4)
- SEC Form 10-Q filed by Sensus Healthcare Inc.
- Sensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights
- Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone
- Sensus Healthcare to Report Third Quarter 2026 Financial Results and Hold Business Update Conference Call on November 12, 2026
- Director Sachetta Eric bought $225,616 worth of shares (64,841 units at $3.48), increasing direct ownership by 28% to 294,784 units (SEC Form 4)
- Director Sachetta Eric bought $66,682 worth of shares (20,633 units at $3.23), increasing direct ownership by 10% to 229,943 units (SEC Form 4)
- Director Sachetta Eric bought $112,904 worth of shares (34,697 units at $3.25), increasing direct ownership by 20% to 209,310 units (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Sardano Joseph C bought $60,486 worth of shares (20,000 units at $3.02), increasing direct ownership by 2% to 1,220,293 units (SEC Form 4)